Schrödinger Inc (NASDAQ:SDGR) shares dropped 13.7% following the company’s announcement that it is discontinuing development ...

Citi downgraded Schrodinger ( NASDAQ: SDGR) to Neutral from Buy after the AI-focused biotech announced its decision to discontinue a clinical program for a leukemia candidate following the emergence ...

"Schrödinger ends development of blood cancer drug after patient deaths" was originally created and published by Clinical ...

Third Patient Treated with HG-CT-1 CAR-T Therapy and Completion of First Adult Dose Cohort LONDON, UNITED KINGDOM / ACCESS ...

(Alliance News) - Hemogenyx Pharmaceuticals PLC on Friday said a third patient has been successfully treated under its phase one trial of its CAR-T cell therapy, HG-CT-1, for relapsed or refractory ...

Programmed death-1 (PD-1) inhibition with pembrolizumab led to durable remission in 31.3% of patients with early acute ...

Schrödinger is abandoning its CDC7 inhibitor after the therapy was linked to the deaths of two patients in a phase 1 leukemia trial. The biotech had been evaluating the asset, dubbed SGR-2921, in an ...

Amir Fathi, MD, leukemia specialist at Massachusetts General Hospital, discusses the importance of advocacy by both patients ...

Childhood acute myeloid leukemia is a type of cancer that affects blood cells in the bone marrow. Learn more about this condition, including symptoms, how it’s diagnosed, treatments, and more.

There's light at the end of the tunnel for Kendall Schara in her fight against Acute Myeloid Leukemia, after her sister Elle ...

One 2021 study looked at acute leukemia diagnosed during pregnancy between the years 2010 to 2019. It included 21 pregnant people with acute leukemia, including 18 with AML.